Scott L Mitchell

US Patent:

20200392153, Dec 17, 2020

Filed:

May 21, 2020

Appl. No.:

16/880134

Inventors:

- Foster City CA, US
Jayaraman Chandrasekhar - Redmond WA, US
Julian A. Codelli - Seattle WA, US
John H. Conway - Seattle WA, US
Kristyna M. Elbel - San Francisco CA, US
Rao V. Kalla - Cupertino CA, US
Samuel E. Metobo - Newark CA, US
Scott A. Mitchell - Kenmore WA, US
Thao D. Perry - San Jose CA, US
Scott P. Simonovich - San Francisco CA, US

International Classification:

C07D 498/04
C07D 413/14
C07D 519/00
C07D 471/04

Abstract:

The present disclosure relates generally to certain ene-oxindole compounds, pharmaceutical compositions comprising thereof. Also disclosed are methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.

US Patent:

20180280387, Oct 4, 2018

Filed:

Feb 28, 2018

Appl. No.:

15/907858

Inventors:

- Foster City CA, US
Astrid Clarke - Bainbridge Island WA, US
Kevin S. Currie - North Bend WA, US
Julie A. Di Paolo - San Francisco CA, US
Jeffrey E. Kropf - Issaquah WA, US
Seung H. Lee - Sammamish WA, US
Jennifer R. Lo - Seattle WA, US
Scott A. Mitchell - Kenmore WA, US
Aaron C. Schmitt - Hamden CT, US
Sundaramoorthi Swaminathan - Burlingame CA, US
Jin-Ming Xiong - Guilford CT, US
Jianjun Xu - Seattle WA, US
Zhongdong Zhao - Bellevue WA, US

International Classification:

A61K 31/4985
A61K 31/5377
A61K 31/519
A61K 31/475

Abstract:

The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I:wherein R, R, R, and Rare as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk. In certain embodiments, also disclosed are methods for treating a cancer in a subject (e.g., a human) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, in combination with a vinca-alkaloid, or a pharmaceutically acceptable salt thereof.

US Patent:

20170035755, Feb 9, 2017

Filed:

Oct 20, 2016

Appl. No.:

15/298950

Inventors:

- Foster City CA, US
ASTRID CLARKE - Bainbridge Island WA, US
KEVIN S. CURRIE - North Bend WA, US
JULIE A. DI PAOLO - San Francisco CA, US
JEFFREY E. KROPF - Issaquah WA, US
SEUNG H. LEE - Sammamish WA, US
JENNIFER R. LO - Seattle WA, US
SCOTT A. MITCHELL - Kenmore WA, US
AARON C. SCHMITT - Hamden CT, US
SUNDARAMOORTHI SWAMINATHAN - Burlingame CA, US
JIN-MING XIONG - Guilford CT, US
JIANJUN XU - Seattle WA, US
ZHONGDONG ZHAO - Bellevue WA, US

International Classification:

A61K 31/4985
A61K 31/475
A61K 31/5377

Abstract:

The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I:wherein R, R, R, and Rare as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk. In certain embodiments, also disclosed are methods for treating a cancer in a subject (e.g., a human) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, in combination with a vinca-alkaloid, or a pharmaceutically acceptable salt thereof.

US Patent:

20160368918, Dec 22, 2016

Filed:

May 9, 2016

Appl. No.:

15/150038

Inventors:

- Foster City CA, US
Jayaraman Chandrasekhar - Redmond WA, US
Kevin S. Currie - North Bend WA, US
Zhimin Du - Belmont CA, US
Julie Farand - San Mateo CA, US
Juan A. Guerrero - Concord CA, US
Ashley A. Katana - North Olmsted OH, US
Darryl Kato - San Francisco CA, US
Jeffrey Kropf - Issaquah WA, US
Scott E. Lazerwith - San Francisco CA, US
Seung H. Lee - Sammamish WA, US
Jiayao Li - Foster City CA, US
John O. Link - San Francisco CA, US
Jennifer R. Lo - Seattle WA, US
Nicholas Mai - San Jose CA, US
Scott A. Mitchell - Kenmore WA, US
Gregory Notte - San Mateo CA, US
Hyung-jung Pyun - Fremont CA, US
Michael Sangi - San Mateo CA, US
Aaron C. Schmitt - Hamden CT, US
Adam J. Schrier - Redwood City CA, US
Kirk L. Stevens - Bothell WA, US
Chandrasekar Venkataramani - Redwood City CA, US
William J. Watkins - Saratoga CA, US
Jin Ming Xiong - Guilford CT, US
Jianjun Xu - Seattle WA, US
Zheng-Yu Yang - Palo Alto CA, US
Jeff Zablocki - Los Altos CA, US
Zhongdong Zhao - Bellevue WA, US
Sheila Zipfel - San Mateo CA, US

International Classification:

C07D 471/04
C07D 403/14
C07D 401/14
C07D 519/00
C07D 487/04
C07D 498/04
C07D 413/14
C07D 405/14
C07D 417/12
C07D 417/14
C07D 403/12
C07D 491/08

Abstract:

The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I:wherein X, X, X, R, R, R, R, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.